close

Strike action from Thursday 27 June to Tuesday 2 July 2024

Junior doctors at The Christie will strike from 7am on Thursday 27 June until 7am on Tuesday 2 July 2024.

We are proactively contacting patients with appointments that may be affected. If you have an appointment on any of these dates, please continue to come to The Christie and our other centres as planned, unless we contact you to tell you otherwise. Please do not call to check if your appointment is still going ahead.

Skip to Content

Other publications - Alexander Lee

2020

  • LyRIC indeterminate response and confirmed immune-mediated pseudoprogression of refractory diffuse large B cell lymphoma following polatuzumab-based salvage chemoimmunotherapy Lee ATJ, Attygale AD, Iyengar S et al. B J Haem; May 2020
  • Pazopanib as a choice for solitary fibrous tumour. Lee ATJ, Benson C. Lancet Oncol 2020 Mar;21(3):332-333. doi: 10.1016/S1470-2045(20)30018-8

2019

  • Ewing-like sarcomas: new molecular diagnoses in need of optimised treatment approaches Lee ATJ, Huang PH, Jones RL. Indian J Med Res. 2019 Dec; 150(6): 521–523.
  • Negative phase III trials announce the need for biomarkers in sarcoma Lee ATJ, Huang PH, Jones RL. Eur J Cancer 2019. 123; 81-82. doi: 10.1016/j.ejca.2019.08.035
  • Pazopanib in advanced soft tissue sarcomas. Lee ATJ, Jones RL, Huang PH. Sig Trans Targ Ther 2019; 4: 16. doi: 10.1038/s41392-019-0049-6
  • The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. Lee ATJ, Chew W, Wilding CM et al. Sci Rep 2019; 9,14602. doi:10.1038/s41598-019-50888-5

2018

  • Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Chew W, Benson C, Thway K et al. Medical Oncology 2018. 35(11):138. doi: 10.1007/s12032-018-1192-6
  • Clinical and molecular spectrum of liposarcoma. Lee ATJ, Thway K, Huang PH, Jones RL. J Clin Oncol 2018. 36(2): 151-159. doi: 10.1200/JCO.2017.74.9598
  • Olaratumab in soft tissue sarcoma – Current status and future perspectives. Antoniou G, Lee ATJ, Huang P, Jones RL. Eur J Cancer 2018; 92:33-39. doi: 10.1016/j.ejca.2017.12.026
  • 2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma Frezza AM, Lee ATJ, Nizri E et al. ESMO Open 2018;3:e000390.doi:10.1136/esmoopen-2018-000390

2015 - 2017

  • Progress and Impact of clinical phosphoproteomics on precision oncology Lima N*, Lee A*, Huang P. Translational Cancer Research 2017;6(Suppl 6):S1108-S1114. doi: 10.21037/tcr.2017.07.05
  • Phase III soft tissue sarcoma trials: Success or Failure? Lee A, Pollack S, Huang P & Jones R. Current Treatment Options in Oncology 2017; 18(3):19. Doi: 10.1007/s11864-017-0457-1
  • Novel therapeutic approaches in chondrosarcoma Polychronidou G, Karavasilis V, Pollack S, Huang P, Lee A, Jones R. Future Oncology. 2017 Mar; 13(7). doi: 10.2217/fon-2016-0226
  • Immunotherapy for Soft Tissue Sarcoma - Tomorrow is Only a Day Away Lee A, Huang P, DeMatteo R, & Pollack S.  ASCO Educational Book 2016;35;281-90. doi: 10.14694/EDBK_157439
  • Drug repositioning in sarcomas and other rare tumours Lee A, Huang P, Pollack S, Jones R. EBioMedicine (2016). doi:10.1016/j.ebiom.2016.03.021
  • Prognostic score for patients with advanced melanoma treated with ipilimumab Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, Larkin J
  • European Journal of Cancer 2015. 51, 2785–91. doi: 10.1016/j.ejca.2015.09.007

Last updated: January 2023

© 2024 The Christie NHS Foundation Trust